Bruce Jacobs Sells 7,576 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CFO Bruce Jacobs sold 7,576 shares of Kymera Therapeutics stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $88.93, for a total value of $673,733.68. Following the completion of the transaction, the chief financial officer directly owned 237,483 shares of the company’s stock, valued at $21,119,363.19. This represents a 3.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Kymera Therapeutics Stock Performance

Shares of NASDAQ KYMR traded down $0.24 during mid-day trading on Wednesday, reaching $86.11. The company had a trading volume of 1,043,150 shares, compared to its average volume of 809,415. The firm has a market cap of $7.03 billion, a price-to-earnings ratio of -23.40 and a beta of 2.20. The business’s 50-day simple moving average is $78.69 and its 200 day simple moving average is $66.27. Kymera Therapeutics, Inc. has a one year low of $19.44 and a one year high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The firm had revenue of $2.87 million for the quarter, compared to analyst estimates of $14.80 million. During the same quarter in the previous year, the company earned ($0.88) earnings per share. The company’s quarterly revenue was down 60.8% on a year-over-year basis. On average, sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on KYMR. Wells Fargo & Company boosted their price objective on shares of Kymera Therapeutics from $69.00 to $116.00 and gave the company an “overweight” rating in a research report on Tuesday, December 9th. BTIG Research decreased their price target on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Barclays boosted their price target on Kymera Therapeutics to $133.00 and gave the stock an “overweight” rating in a report on Tuesday, January 27th. Oppenheimer raised their price objective on Kymera Therapeutics from $67.00 to $120.00 and gave the company an “outperform” rating in a research note on Tuesday, December 9th. Finally, Morgan Stanley reissued an “overweight” rating and set a $123.00 target price on shares of Kymera Therapeutics in a research note on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $119.50.

Institutional Investors Weigh In On Kymera Therapeutics

Several hedge funds have recently modified their holdings of the company. Federated Hermes Inc. acquired a new position in shares of Kymera Therapeutics in the third quarter valued at approximately $31,622,000. China Universal Asset Management Co. Ltd. grew its holdings in Kymera Therapeutics by 77.2% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 23,079 shares of the company’s stock worth $1,007,000 after acquiring an additional 10,052 shares during the last quarter. Candriam S.C.A. increased its position in Kymera Therapeutics by 24.4% in the 3rd quarter. Candriam S.C.A. now owns 191,639 shares of the company’s stock valued at $10,847,000 after acquiring an additional 37,536 shares during the period. Frontier Capital Management Co. LLC increased its position in Kymera Therapeutics by 272.7% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 491,810 shares of the company’s stock valued at $21,463,000 after acquiring an additional 359,847 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH raised its stake in shares of Kymera Therapeutics by 26.3% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 107,438 shares of the company’s stock valued at $4,689,000 after acquiring an additional 22,392 shares during the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.